TSE:ONC

Oncolytics Biotech (ONC) Competitors

C$2.28

+0.04 (+1.79%)

(As of 06/2/2023 05:42 PM ET)

Compare

Today's Range: C$2.21
▼
C$2.30
50-Day Range: C$1.51
▼
C$2.93
52-Week Range: C$1.06
▼
C$3.10

Volume: 103,670 shs
Average Volume: 55,145 shs
Market Capitalization: C$146.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$6.75

Profile Analyst Ratings Chart Competitors Earnings Insider Trades Headlines Social Media

ONC vs. IPA, BCT, TH, SCYB, COM, NVH, IGX, PDP, PMN, and MDNA

Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include ImmunoPrecise Antibodies (IPA), BriaCell Therapeutics (BCT), Theratechnologies (TH), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Pediapharm (PDP), ProMIS Neurosciences (PMN), and Medicenna Therapeutics (MDNA). These companies are all part of the "biotechnology" industry.

Oncolytics Biotech vs.

ImmunoPrecise Antibodies (CVE:IPA) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.

: In the previous week, Oncolytics Biotech had 3 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 3 mentions for Oncolytics Biotech and 0 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 0.00 equaled Oncolytics Biotech's average media sentiment score.
Company Overall Sentiment
ImmunoPrecise Antibodies Neutral
Oncolytics Biotech Neutral
: 1.5% of Oncolytics Biotech shares are held by institutional investors. 1.3% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: Oncolytics Biotech received 153 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. Likewise, 75.10% of users gave Oncolytics Biotech an outperform vote while only 54.79% of users gave ImmunoPrecise Antibodies an outperform vote.
Company Underperform Outperform
ImmunoPrecise Antibodies Outperform Votes
40
54.79%
Underperform Votes
33
45.21%
Oncolytics Biotech Outperform Votes
193
75.10%
Underperform Votes
64
24.90%
: ImmunoPrecise Antibodies has higher revenue and earnings than Oncolytics Biotech. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunoPrecise Antibodies C$19.47 million 8.33 -C$22.19 million -C$0.89 -7.30
Oncolytics Biotech N/A N/A -C$24.49 million -C$0.42 -5.43
: ImmunoPrecise Antibodies' return on equity of 0.00% beat Oncolytics Biotech's return on equity.
Company Net Margins Return on Equity Return on Assets
ImmunoPrecise Antibodies N/A N/A N/A
Oncolytics Biotech N/A -80.61% -42.85%
: Oncolytics Biotech has a consensus target price of C$6.75, indicating a potential upside of 196.05%. Given Oncolytics Biotech's higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than ImmunoPrecise Antibodies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunoPrecise Antibodies
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Oncolytics Biotech
0 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
3.00

Company	Overall Sentiment
ImmunoPrecise Antibodies	Neutral
Oncolytics Biotech	Neutral

Company	Underperform	Outperform
ImmunoPrecise Antibodies	Outperform Votes 40 54.79%	Underperform Votes 33 45.21%
Oncolytics Biotech	Outperform Votes 193 75.10%	Underperform Votes 64 24.90%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoPrecise Antibodies	C$19.47 million	8.33	-C$22.19 million	-C$0.89	-7.30
Oncolytics Biotech	N/A	N/A	-C$24.49 million	-C$0.42	-5.43

Company	Net Margins	Return on Equity	Return on Assets
ImmunoPrecise Antibodies	N/A	N/A	N/A
Oncolytics Biotech	N/A	-80.61%	-42.85%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunoPrecise Antibodies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Oncolytics Biotech	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Oncolytics Biotech beats ImmunoPrecise Antibodies on 9 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONC vs. The Competition

Export to Excel

Metric	Oncolytics Biotech	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$146.13M	C$225.32M	C$4.45B	C$3.58B
Dividend Yield	N/A	2.69%	5.95%	7.04%
P/E Ratio	-5.43	339.83	82.73	24.04
Price / Sales	N/A	23,059.86	3,368.04	1,085.30
Price / Cash	4.22	10.49	22.00	72.77
Price / Book	5.70	4.55	4.73	3.97
Net Income	-C$24.49M	-C$15.93M	C$115.49M	C$325.22M
7 Day Performance	-10.24%	5.35%	121.56%	1.13%
1 Month Performance	6.54%	3.94%	123.55%	-3.29%
1 Year Performance	61.70%	123.37%	135.83%	7.75%

Oncolytics Biotech Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPA ImmunoPrecise Antibodies	0 of 5 stars	C$6.50 +0.8%	N/A	-7.4%	C$162.08M	C$19.47M	-7.30	73	Gap Down
BCT BriaCell Therapeutics	0 of 5 stars	C$10.60 -3.8%	N/A	+0.0%	C$168.68M	N/A	-28.19	5
TH Theratechnologies	0 of 5 stars	C$1.24 +0.8%	C$2.25 +81.5%	-62.9%	C$120.04M	C$81.41M	-1.82	87
SCYB Scythian Biosciences	0 of 5 stars	C$3.49 -5.9%	N/A	+0.0%	C$102.38M	N/A	0.00	N/A	High Trading Volume
COM 138267 (COM.TO)	0 of 5 stars	C$2.95 -2.6%	N/A	N/A	C$102.19M	N/A	0.00	N/A
NVH Novoheart	0 of 5 stars	C$0.53 +1.9%	N/A	+0.0%	C$99.98M	C$423,500.00	-13.95	N/A
IGX IntelGenx Technologies	0 of 5 stars	C$0.58 +1.8%	N/A	+0.0%	C$87.32M	C$1.75M	-7.44	48	Gap Up
PDP Pediapharm	0 of 5 stars	C$0.30 +1.7%	N/A	+0.0%	C$66.36M	C$11.16M	-4.11	N/A
PMN ProMIS Neurosciences	0 of 5 stars	C$6.85 -2.8%	N/A	+5,809.1%	C$58.77M	C$7,558.00	-1.85	5
MDNA Medicenna Therapeutics	0 of 5 stars	C$0.81 +1.3%	C$5.33 +558.4%	-34.2%	C$56.41M	N/A	-5.40	13	Gap Up

Related Companies and Tools

This page (TSE:ONC) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oncolytics Biotech (ONC) Competitors

ONC vs. IPA, BCT, TH, SCYB, COM, NVH, IGX, PDP, PMN, and MDNA

Oncolytics Biotech vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info